Drugs / sapacitabine
sapacitabine
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03641755 | Oct 2018 → Apr 2022 overdue | breast cancer | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00999401 | Apr 2009 → Jul 2019 | cancer | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00380653 | Jan 2006 → Nov 2008 | leukemia, myelodysplastic syndrome | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01211457 | Jun 2010 → Jun 2020 | acute myeloid leukemia, myelodysplastic syndrome | Cyclacel Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01253460 | Aug 2011 → Mar 2018 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00885963 | Dec 2008 → Aug 2013 | non-small cell lung carcinoma | Cyclacel Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00590187 | Dec 2007 → Dec 2018 | acute myeloid leukemia | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00476554 | Apr 2007 → Mar 2012 | primary cutaneous T-cell lymphoma | Cyclacel Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01303796 | Oct 2011 → Dec 2016 | acute myeloid leukemia | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sapacitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03641755 ↗ |
| Known as | CS-682 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105681 ↗ |
| Known as | CYC-682 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105681 ↗ |
| Known as | Sapacitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105681 ↗ |
| Modality | Small molecule | “Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine.” PMID 19933907 ↗ Nov 2009 |
| Route | Oral | “To define the dose-limiting toxicities (DLT) and maximum-tolerated dose (MTD) of sapacitabine given orally twice daily for 7 days every 3 to 4 weeks, or twice daily for 3 days...” PMID 19933907 ↗ Nov 2009 |